Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
DOI:
https://doi.org/10.12775/JEHS.2024.75.56672Keywords
obesity, antipsychotic-induced weight gain, clozapine, olanzapine, adverse effect, GLP-1 receptors agonistAbstract
Introduction
Obesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the risk of metabolic syndrome. Recent advances with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, show promise in addressing antipsychotic-induced obesity by reducing weight and improving metabolic health.
Purpose
The aim of this review is to present an overview of the current state of knowledge regarding the efficacy of GLP-1 RAs in the treatment of antipsychotic-induced obesity.
Materials and methods
This review is based on both original research studies and review articles identified through a comprehensive search of the PubMed database, using the following search terms: obesity, antipsychotic-induced weight gain, clozapine, olanzapine, adverse effect, GLP-1 receptors agonist.
Description of the state of knowledge
GLP-1 RAs significantly reduce body weight and adipose tissue by suppressing appetite, particularly for high-fat foods. Clinical trials show improvements in lipid profiles, blood pressure, and inflammation, contributing to better metabolic health. However, their long-term effects, especially with different antipsychotics, remain insufficiently studied.
Conclusions
GLP-1 RAs show significant potential for managing antipsychotic-induced obesity, but further research is needed to assess long-term efficacy and safety in this population.
References
Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S,
Kissling W, Davis JM, Leucht S. Maintenance treatment with antipsychotic drugs for
schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016. doi:
1002/14651858.CD008016.pub3. PMID: 32840872; PMCID: PMC9702459.
Ameer MA, Patel P, Saadabadi A. Neuroleptic Medications. 2024 Feb 21. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID:
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B,
Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and
risks associated with first- and second-generation antipsychotics: a state-of-the-art
clinical review. Ther Clin Risk Manag. 2017 Jun 29;13:757-777. doi:
2147/TCRM.S117321. PMID: 28721057; PMCID: PMC5499790.
Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam
Physician. 2010 Mar 1;81(5):617-22. PMID: 20187598.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ.
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J
Psychiatry. 1999 Nov;156(11):1686-96. doi: 10.1176/ajp.156.11.1686. PMID:
Kar N, Barreto S. Influence of Lifestyle Factors on Metabolic Syndrome in
Psychiatric Patients Attending a Community Mental Health Setting: A Cross-sectional
Study. Indian J Psychol Med. 2024 Jul;46(4):313-322. doi:
1177/02537176231219770. Epub 2024 Jan 31. PMID: 39056040; PMCID:
PMC11268271.
Miñambres I, Rubio-Herrera MÁ, Nicolau J, Milad C, Morales MJ, Bueno M,
Calañas A, Carceller-Sindreu M, de Hollanda A; Obesity Area of the Spanish Society
of Endocrinology and Nutrition (ObesitySEEN). Outcomes of Bariatric Surgery in
Patients with Schizophrenia. Nutrients. 2024 Jul 31;16(15):2487. doi:
3390/nu16152487. PMID: 39125367; PMCID: PMC11313780.
de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N,
Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight
gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341.
doi: 10.1186/s12888-016-1049-5. PMID: 27716110; PMCID: PMC5048618.
Khaity A, Mostafa Al-Dardery N, Albakri K, Abdelwahab OA, Hefnawy MT, Yousef
YAS, Taha RE, Swed S, Hafez W, Hurlemann R, Elsayed MEG. Glucagon-like
peptide-1 receptor-agonists treatment for cardio-metabolic parameters in
schizophrenia patients: a systematic review and meta-analysis. Front Psychiatry. 2023
May 5;14:1153648. doi: 10.3389/fpsyt.2023.1153648. PMID: 37215670; PMCID:
PMC10196269.
Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp
Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. PMID: 21484567.
Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily
human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and
glucose intolerance. Schizophr Res. 2008 Aug;103(1-3):94-103. doi:
1016/j.schres.2008.05.011. Epub 2008 Jun 25. PMID: 18579346.
De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The Use of
Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in
Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of
Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
CNS Drugs. 2015 Aug;29(8):637-58. doi: 10.1007/s40263-015-0269-4. PMID:
Rognoni C, Bertolani A, Jommi C. Second-Generation Antipsychotic Drugs for
Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of
Metabolic and Cardiovascular Side Effects. Clin Drug Investig. 2021
Apr;41(4):303-319. doi: 10.1007/s40261-021-01000-1. Epub 2021 Mar 9. PMID:
; PMCID: PMC8004512.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO,
Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J
Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep
Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3. PMID: 16172203.
Chan JKN, Correll CU, Wong CSM, Chu RST, Fung VSC, Wong GHS, Lei JHC,
Chang WC. Life expectancy and years of potential life lost in people with mental
disorders: a systematic review and meta-analysis. EClinicalMedicine. 2023 Oct
;65:102294. doi: 10.1016/j.eclinm.2023.102294. PMID: 37965432; PMCID:
PMC10641487.
Wildgust HJ, Hodgson R, Beary M. The paradox of premature mortality in
schizophrenia: new research questions. J Psychopharmacol. 2010 Nov;24(4
Suppl):9-15. doi: 10.1177/1359786810382149. PMID: 20923916; PMCID:
PMC2951588.
Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain.
Psychopharmacology (Berl). 2004 Aug;174(4):477-89. doi:
1007/s00213-004-1949-9. Epub 2004 Jul 8. PMID: 15243737.
Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From
Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol.
;16(8):1210-1223. doi: 10.2174/1570159X15666170630163616. PMID:
; PMCID: PMC6187748.
Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and
antipsychotics: new findings from animal model and pharmacogenomic studies.
Schizophr Res Treatment. 2011;2011:459284. doi: 10.1155/2011/459284. Epub 2010
Dec 6. PMID: 22988505; PMCID: PMC3440684.
Mukherjee S, Skrede S, Milbank E, Andriantsitohaina R, López M, Fernø J.
Understanding the Effects of Antipsychotics on Appetite Control. Front Nutr. 2022
Jan 3;8:815456. doi: 10.3389/fnut.2021.815456. PMID: 35047549; PMCID:
PMC8762106.
Zhao S, Lin Q, Xiong W, Li L, Straub L, Zhang D, Zapata R, Zhu Q, Sun XN, Zhang
Z, Funcke JB, Li C, Chen S, Zhu Y, Jiang N, Li G, Xu Z, Wyler SC, Wang MY, Bai J,
Han X, Kusminski CM, Zhang N, An Z, Elmquist JK, Osborn O, Liu C, Scherer PE.
Hyperleptinemia contributes to antipsychotic drug-associated obesity and metabolic
disorders. Sci Transl Med. 2023 Nov 22;15(723):eade8460. doi:
1126/scitranslmed.ade8460. Epub 2023 Nov 22. PMID: 37992151.
Ak M, Sezlev D, Sutcigil L, Akarsu S, Ozgen F, Yanik T. The investigation of leptin
and hypothalamic neuropeptides role in first attack psychotic male patients:
olanzapine monotherapy. Psychoneuroendocrinology. 2013 Mar;38(3):341-7. doi:
1016/j.psyneuen.2012.06.012. Epub 2012 Jul 26. PMID: 22840286.
Chen CY, Goh KK, Chen CH, Lu ML. The Role of Adiponectin in the Pathogenesis
of Metabolic Disturbances in Patients With Schizophrenia. Front Psychiatry. 2021 Jan
;11:605124. doi: 10.3389/fpsyt.2020.605124. PMID: 33551872; PMCID:
PMC7854923.
Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on
leptin, ghrelin, and adiponectin. Schizophr Res. 2008 Mar;100(1-3):70-85. doi:
1016/j.schres.2007.11.026. Epub 2008 Jan 18. PMID: 18206351; PMCID:
PMC2699769.
Kornetova EG, Kornetov AN, Mednova IA, Dubrovskaya VV, Boiko AS, Bokhan
NA, Loonen AJM, Ivanova SA. Changes in Body Fat and Related Biochemical
Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia
Patients With or Without Metabolic Syndrome. Front Psychiatry. 2019 Nov 1;10:803.
doi: 10.3389/fpsyt.2019.00803. PMID: 31736812; PMCID: PMC6838009.
Fernø J, Skrede S, Vik-Mo AO, Håvik B, Steen VM. Drug-induced activation of
SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked
differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
doi: 10.1186/1471-2202-7-69. PMID: 17052361; PMCID: PMC1635424.
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva
VA. Antipsychotic-associated weight gain: management strategies and impact on
treatment adherence. Neuropsychiatr Dis Treat. 2017 Aug 22;13:2231-2241. doi:
2147/NDT.S113099. PMID: 28883731; PMCID: PMC5574691.
Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, Altowarqi
NA, Alzahrani H, Alshehri AM, Alkhaldi RK, Alqahtani KW, Alharbi NH, Alhulayfi
HF, Sharifi SY, Dighriri IM. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists:
Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a
Comprehensive Literature Review. Cureus. 2024 Sep 1;16(9):e68390. doi:
7759/cureus.68390. PMID: 39355484; PMCID: PMC11444311.
Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of
GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled
Trials. Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449. PMID:
; PMCID: PMC10341852.
Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1
receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024
Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z. PMID: 39289339; PMCID:
PMC11408715.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007
Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006. PMID: 17928588.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment
of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi:
1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776; PMCID:
PMC8085572.
Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin
secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes
Metab. 2013 Jan;15(1):15-27. doi: 10.1111/j.1463-1326.2012.01663.x. Epub 2012
Aug 1. PMID: 22776039; PMCID: PMC3556522.
Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based
therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530.
doi: 10.1155/2011/279530. Epub 2011 Jun 22. PMID: 21747825; PMCID:
PMC3124003.
Neary NM, Goldstone AP, Bloom SR. Appetite regulation: from the gut to the
hypothalamus. Clin Endocrinol (Oxf). 2004 Feb;60(2):153-60. doi:
1046/j.1365-2265.2003.01839.x. PMID: 14725674.
Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the
Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021
Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11. PMID:
; PMCID: PMC8189979.
Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab.
Mar;57:101351. doi: 10.1016/j.molmet.2021.101351. Epub 2021 Oct 6. PMID:
; PMCID: PMC8859548.
Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The Emerging Role of
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic
Dysfunction-Associated Steatohepatitis. Clin Gastroenterol Hepatol. 2024
Aug;22(8):1565-1574. doi: 10.1016/j.cgh.2024.01.032. Epub 2024 Feb 15. PMID:
Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1
Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne).
Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. PMID: 34497589;
PMCID: PMC8419463.
Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in
cardiovascular diseases. Front Clin Diabetes Healthc. 2023 Dec 8;4:1293926. doi:
3389/fcdhc.2023.1293926. PMID: 38143794; PMCID: PMC10739421.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA,
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B,
Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial
Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J
Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
PMID: 27295427; PMCID: PMC4985288.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I,
Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J,
Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in
Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi:
1056/NEJMoa1607141. Epub 2016 Sep 15. PMID: 27633186.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield
J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S,
Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC,
Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA,
Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ,
Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide
and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,
randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi:
1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. PMID: 31189511.
Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight
Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J
ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub
Aug 23. PMID: 36578889; PMCID: PMC9758543.
Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1
Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022
Jan 1;107(1):29-38. doi: 10.1210/clinem/dgab578. PMID: 34406410; PMCID:
PMC8684453.
Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F.
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in
Neurodegenerative Diseases. Int J Mol Sci. 2022 Aug 24;23(17):9583. doi:
3390/ijms23179583. PMID: 36076972; PMCID: PMC9455625.
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A,
Cebrián-Cuenca A, de Torres-Sánchez A, García-de-Lucas MD, Núñez J, Obaya JC,
Soler MJ, Górriz JL, Rubio-Herrera MÁ. Clinical Recommendations to Manage
Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A
Multidisciplinary Expert Consensus. J Clin Med. 2022 Dec 24;12(1):145. doi:
3390/jcm12010145. PMID: 36614945; PMCID: PMC9821052.
Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan
M. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying,
Food Preference and Taste Among Adults with Obesity: Systematic Review of
Randomized Controlled Trials. Diabetes Metab Syndr Obes. 2023 Mar 2;16:575-595.
doi: 10.2147/DMSO.S387116. PMID: 36890965; PMCID: PMC9987242.
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike
peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2
diabetes mellitus: a population-based matched case-control study. JAMA Intern Med.
Apr 8;173(7):534-9. doi: 10.1001/jamainternmed.2013.2720. PMID: 23440284.
He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. Association of
Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary
Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
JAMA Intern Med. 2022 May 1;182(5):513-519. doi:
1001/jamainternmed.2022.0338. PMID: 35344001; PMCID: PMC8961394.
Gether IM, Nexøe-Larsen C, Knop FK. New Avenues in the Regulation of
Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived
Drugs. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2463-2472. doi:
1210/jc.2018-01008. PMID: 30137354.
Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Hypoglycemia following the use of
glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing
surveillance data. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162.
PMID: 34734034; PMCID: PMC8506728.
Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the
Treatment of Type 2 Diabetes. 2024 Sep 11. In: Feingold KR, Anawalt B, Blackman
MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K,
Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS,
Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J,
Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP,
editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
PMID: 25905364.
Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK,
Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT,
Correll CU, Vilsbøll T, Fink-Jensen A. Effect of Liraglutide Treatment on Prediabetes
and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With
Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry.
Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220. PMID: 28601891;
PMCID: PMC5710254.
Prasad F, De R, Korann V, Chintoh AF, Remington G, Ebdrup BH, Siskind D, Knop
FK, Vilsbøll T, Fink-Jensen A, Hahn MK, Agarwal SM. Semaglutide for the
treatment of antipsychotic-associated weight gain in patients not responding to
metformin - a case series. Ther Adv Psychopharmacol. 2023 Apr
;13:20451253231165169. doi: 10.1177/20451253231165169. Erratum in: Ther Adv
Psychopharmacol. 2024 May 28;14:20451253241258536. doi:
1177/20451253241258536. PMID: 37113745; PMCID: PMC10126648.
Ishøy PL, Knop FK, Broberg BV, Bak N, Andersen UB, Jørgensen NR, Holst JJ,
Glenthøj BY, Ebdrup BH. Effect of GLP-1 receptor agonist treatment on body weight
in obese antipsychotic-treated patients with schizophrenia: a randomized,
placebo-controlled trial. Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi:
1111/dom.12795. Epub 2016 Nov 14. Erratum in: Diabetes Obes Metab. 2018
May;20(5):1327-1328. doi: 10.1111/dom.13204. PMID: 27717222; PMCID:
PMC5299524.
Lee K, Abraham S, Cleaver R. A systematic review of licensed weight-loss
medications in treating antipsychotic-induced weight gain and obesity in
schizophrenia and psychosis. Gen Hosp Psychiatry. 2022 Sep-Oct;78:58-67. doi:
1016/j.genhosppsych.2022.07.006. Epub 2022 Jul 14. PMID: 35863294.
Bak M, Campforts B, Domen P, van Amelsvoort T, Drukker M. Glucagon-like
peptide agonists for weight management in antipsychotic-induced weight gain: A
systematic review and meta-analysis. Acta Psychiatr Scand. 2024
Dec;150(6):516-529. doi: 10.1111/acps.13734. Epub 2024 Jul 24. PMID: 39048532.
Mansur RB, Lee Y, Subramaniapillai M, Brietzke E, McIntyre RS. Cognitive
dysfunction and metabolic comorbidities in mood disorders: A repurposing
opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. 2018
Jul 1;136(Pt B):335-342. doi: 10.1016/j.neuropharm.2018.01.048. Epub 2018 Feb 23.
PMID: 29481915.
McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M,
Woldeyohannes HO, Kim AS, Gallaugher LA. The neuroprotective effects of GLP-1:
possible treatments for cognitive deficits in individuals with mood disorders. Behav
Brain Res. 2013 Jan 15;237:164-71. doi: 10.1016/j.bbr.2012.09.021. Epub 2012 Sep
PMID: 23000536.
Cernea S, Dima L, Correll CU, Manu P. Pharmacological Management of Glucose
Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs.
Nov;80(17):1763-1781. doi: 10.1007/s40265-020-01393-x. PMID: 32930957.
Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight
Loss. Curr Obes Rep. 2019 Jun;8(2):156-164. doi: 10.1007/s13679-019-00335-3.
PMID: 30874963; PMCID: PMC6520185.
Zhuo C, Xu Y, Wang H, Zhou C, Liu J, Yu X, Shao H, Tian H, Fang T, Li Q, Chen J,
Xu S, Ma X, Yang W, Yao C, Li B, Yang A, Chen Y, Huang G, Lin C. Clozapine
induces metformin-resistant prediabetes/diabetes that is associated with poor clinical
efficacy in patients with early treatment-resistant schizophrenia. J Affect Disord. 2021
Dec 1;295:163-172. doi: 10.1016/j.jad.2021.08.023. Epub 2021 Aug 23. PMID:
Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2)
Inhibitors. 2023 Jun 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls
Publishing; 2024 Jan–. PMID: 35015430.
Haddad F, Dokmak G, Bader M, Karaman R. A Comprehensive Review on Weight
Loss Associated with Anti-Diabetic Medications. Life (Basel). 2023 Apr
;13(4):1012. doi: 10.3390/life13041012. PMID: 37109541; PMCID:
PMC10144237.
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes
Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020
Apr 3;11:178. doi: 10.3389/fendo.2020.00178. PMID: 32308645; PMCID:
PMC7145895.
Kasina SVSK, Baradhi KM. Dipeptidyl Peptidase IV (DPP IV) Inhibitors. 2023 May
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
PMID: 31194471.
Shelby SR, Labott S, Stout RA. Bariatric surgery: a viable treatment option for
patients with severe mental illness. Surg Obes Relat Dis. 2015 Nov-Dec;11(6):1342-8.
doi: 10.1016/j.soard.2015.05.016. Epub 2015 Jun 3. PMID: 26363716.
Kouidrat Y, Amad A, Stubbs B, Moore S, Gaughran F. Surgical Management of
Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic
Review of Outcomes and Recommendations for Future Research. Obes Surg. 2017
Jul;27(7):1889-1895. doi: 10.1007/s11695-017-2715-5. PMID: 28508277.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Natalia Gniaź, Aleksandra Górska, Wiktor Grela, Jagoda Niewiadomska, Daria Furtak, Dawid Tulej, Paulina Głogowska, Alicja Dziedzic, Dominika Marciniuk, Natalia Marko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 341
Number of citations: 0
